Risk scores are statistical indicators based on prescribing patterns compared to specialty peers. They are NOT allegations of fraud, misconduct, or improper care. Many legitimate medical reasons can explain outlier prescribing.
Read our methodology →Risk Flags
Risk indicators are statistical patterns, not allegations. Learn more
9,471
Total Claims
$3.2M
Drug Cost
576
Beneficiaries
$5,531
Cost/Patient
Risk Score Breakdown 22/100
Score components are additive. Read full methodology
Peer Comparison vs. 106,889 Family Practice providers
+156%
Opioid rate vs peers
6.6% vs 2.6% avg
+418%
Cost per patient vs peers
$5,531 vs $1,068 avg
+170%
Brand preference vs peers
24.3% vs 9.0% avg
⚠️ Opioid + Benzodiazepine Co-Prescriber
This provider prescribes both opioids and benzodiazepines. The FDA has issued a Black Box Warning about the life-threatening risks of concurrent use.
🔎 Data Overview
This provider co-prescribes opioids and benzodiazepines — a combination carrying an FDA Black Box Warning due to increased risk of respiratory depression and death. While sometimes clinically necessary, this combination requires careful justification.
Insights generated from CMS data analysis. Statistical patterns are not accusations — always consider clinical context.
Opioid Prescribing
6.6%
Opioid Rate
626
Opioid Claims
$63K
Opioid Cost
10.5%
Long-Acting Rate
Brand vs Generic
Brand: 2,278 claims · $3.0M
Generic: 7,109 claims · $188K
Top Prescribed Drugs
| Drug (Generic) | Claims | Cost |
|---|---|---|
| Bictegrav/Emtricit/Tenofov Ala | 217 | $838K |
| Dolutegravir Sodium | 86 | $212K |
| Empagliflozin | 178 | $208K |
| Elviteg/Cob/Emtri/Tenof Alafen | 37 | $158K |
| Abacavir/Dolutegravir/Lamivudi | 34 | $129K |
| Emtricitab/Rilpiviri/Tenof Ala | 34 | $123K |
| Dolutegravir Sodium/Lamivudine | 36 | $107K |
| Emtricitabine/Tenofov Alafenam | 49 | $104K |
| Semaglutide | 77 | $93K |
| Dulaglutide | 82 | $81K |
| Sitagliptin Phosphate | 42 | $59K |
| Rivaroxaban | 62 | $55K |
| Dolutegravir/Rilpivirine | 15 | $53K |
| Darunavir/Cob/Emtri/Tenof Alaf | 11 | $53K |
| Apixaban | 41 | $43K |
Prescribing Profile
Patient Profile
65
Avg Age
62%
Female
1.43
Avg Risk Score
Explore More
Data from CMS Medicare Part D Prescriber Public Use File, 2023. Risk scores are statistical indicators, not allegations of wrongdoing.Methodology · About · Dispute this data